Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nektar Therapeutics securities during the specified Class Period from February 26, 2025, to December 15, 2025, due to alleged misleading statements and failures to disclose critical information regarding the REZOLVE-AA trial [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and/or misleading statements and failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards [5]. - It is alleged that this failure likely had a significant negative impact on the results of the REZOLVE-AA trial, overstating its overall integrity and prospects [5]. - The lawsuit asserts that when the true details became known, investors suffered damages as a result of the misleading public statements [5]. Group 2: Participation Information - Investors who purchased Nektar securities during the Class Period may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 5, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Navan, Inc. (NASDAQ: NAVN) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the “Offering Documents”) issued in connection with Navan’s October 2025 initial public offering (the “IPO”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court ...

New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.SO WHAT: If you purchased PennyMac securities you may be entitled to compensation without payment of any out of pocket fees or costs through a con ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Navan, Inc. related to its October 2025 IPO, claiming that the Offering Documents were false and misleading [1][5]. Group 1: Lawsuit Details - The class action lawsuit alleges that Navan's Offering Documents omitted critical information regarding increased "sales and marketing" expenses at the time of the IPO, leading to investor damages when the truth was revealed [5]. - Investors who purchased Navan common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. The deadline to move the Court to serve as lead plaintiff is April 24, 2026 [3][5]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PayPal Holdings, Inc. common stock between February 25, 2025, and February 2, 2026, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought PayPal stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 20, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its number of settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3] Group 3: Case Specifics - The lawsuit alleges that PayPal's management provided overly optimistic statements regarding the company's financial targets and growth potential while concealing material adverse facts about its salesforce capabilities [4] - It is claimed that these misleading statements led to investor damages when the true state of the company was revealed [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026, of the April 14, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought REGENXBIO securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is April 14, 2026, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Background - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [4]. - Defendants made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing adverse facts about the trial's efficacy and safety [4]. - The lawsuit claims that when the true details became known, investors suffered damages [4].

New York, New York--(Newsfile Corp. - March 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Richtech Robotics Inc. (NASDAQ: RR) between January 27, 2026 and 12:00 PM ET on January 29, 2026, both dates inclusive (the "Class Period"), of the important April 3, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.SO WHAT: If you purchased Richtech Robotics securities during the Class Period you may be entitled to compensatio ...

New York, New York--(Newsfile Corp. - March 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lakeland Industries, Inc. (NASDAQ: LAKE) between December 1, 2023 and December 9, 2025, inclusive (the "Class Period"), of the important April 24, 2026 lead plaintiff deadline.SO WHAT: If you purchased Lakeland securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit against Apollo Global Management, Inc. on behalf of investors who purchased securities between May 10, 2021, and February 21, 2026, alleging misleading statements and undisclosed communications with Jeffrey Epstein [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Apollo Global's leadership, including Marc Rowan and Leon Black, had frequent communications with Jeffrey Epstein, contradicting the company's public assertion of no business relationship with him [5]. - It is alleged that the entanglement with Epstein harmed Apollo Global's reputation, leading to materially false and misleading statements about its business and operations [5]. - Investors are said to have suffered damages when the true details of these communications became public [5]. Group 2: Participation Information - Investors who purchased Apollo Global securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the court by May 1, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Boston Scientific Corporation for allegedly misleading investors regarding the performance of its U.S. Electrophysiology segment during the Class Period from July 23, 2025, to February 3, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Boston Scientific made positive statements while concealing material adverse facts about the sustainability of its Electrophysiology segment's growth rate, leading to a net income miss and disappointing guidance for the first half of fiscal 2026 [5]. - Investors who purchased common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by May 4, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].